Construction of HCC-targeting artificial miRNAs using natural miRNA precursors

Experimental and Therapeutic Medicine

Volumn 6, Issue 1, 2013, Pages 209-215

  Huang, Xiaoming ^a   Jia, Zhenyu ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Artificial microRNA; Gene therapy; Hepatocellular carcinoma; MicroRNA precursor structure

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 221;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXPRESSION VECTOR; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR CLONING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84878213175     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1111     Document Type: Article

References (33)

1. Mathers C, Fat DM and Boerma J: The global burden of disease: 2004 update. World Health Organization, 2008.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Campbell TN and Choy FY: RNA interference: past, present and future. Curr Issues Mol Biol 7: 1-6, 2005.
4. Sledz CA and Williams BRG: RNA interference in biology and disease. Blood 106: 787-794, 2005.
5. Que XY, Li Y, Han Y and Li XZ: Effects of siRNA-mediated Cdc2 silencing on MG63 cell proliferation and apoptosis. Mol Med Rep 7: 466-470, 2013.
6. Yin Y, Chen X, Zhang CD, et al: Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo. Int J Oncol 42: 253-260, 2013.
7. Boudreau RL, Martins I and Davidson BL: Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17: 169-175, 2009.
8. Liu X, Fang H, Chen H, et al: An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One 7: e38659, 2012.
9. Slezak-Prochazka I, Durmus S, Kroesen BJ and van den BergA: MicroRNAs, macrocontrol: regulation of miRNA processing. RNA 16: 1087-1095, 2010.
10. Starega-Roslan J, Koscianska E, Kozlowski P and KrzyzosiakWJ: The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci 68: 2859-2871, 2011.
11. Zhang KJ, Qian J, Wang SB and Yang Y: Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma. J Biomed Sci 19: 20, 2012.
12. Zhang KJ, Zhang J, Wu YM, et al: Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression. Cancer Gene Ther 19: 619-629, 2012.
13. Han J, Lee Y, Yeom KH, et al: Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 125: 887-901, 2006.
14. Wang Y, Lee AT, Ma JZ, et al: Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 283: 13205-13215, 2008.
15. Bala S, Marcos M and Szabo G: Emerging role of microRNAs in liver diseases. World J Gastroenterol 15: 5633-5640, 2009.
16. Boni V, Bandres E, Zarate R, Colucci G, Maiello E and Garcia-Foncillas J: MicroRNAs as a new potential therapeutic opportunity in gastrointestinal cancer. Oncology 77 (Suppl 1): 75-89, 2009.
17. Li M, Li J, Ding X, He M and Cheng SY: microRNA and cancer. AAPS J 12: 309-317, 2010.
18. Ishida H, Tatsumi T, Hosui A, et al: Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 412: 92-97, 2011.
19. Albulescu R, Neagu M, Albulescu L and Tanase C: Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Rev Mol Diagn 11: 101-120, 2011.
20. Silva JM, Li MZ, Chang K, et al: Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37: 1281-1288, 2005.
21. Xu C, Lee SA and Chen X: RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anticancer Drug Discov 6: 106-115, 2011.
22. Borel F, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56: 1371-1383, 2012.
23. Rutella S, Iudicone P, Bonanno G, et al: Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 14: 841-850, 2012.
24. Shojaei F: Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320: 130-137, 2012.
25. Zeyaullah M, Patro M, Ahmad I, et al: Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 18: 771-781, 2012.
26. Yao N, Yao D, Wang L, et al: Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumour Biol 33: 1767-1776, 2012.
27. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, HartmannRK and Aigner A: MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71: 5214-5224, 2011.
28. Shi ZM, Wang J, Yan Z, et al: MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One 7: e32709, 2012.
29. Stegmeier F, Hu G, Rickles RJ, Hannon GJ and Elledge SJ: A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 102: 13212-13217, 2005.
30. Chang K, Elledge SJ and Hannon GJ: Lessons from Nature: microRNA-based shRNA libraries. Nat Methods 3: 707-714, 2006.
31. Hinton TM, Wise TG, Cottee PA and Doran TJ: Native microRNA loop sequences can improve short hairpin RNA processing for virus gene silencing in animal cells. J RNAi Gene Silencing 4: 295-301, 2008.
32. Zeng Y and Cullen BR: Sequence requirements for micro RNA processing and function in human cells. RNA 9: 112-123, 2003.
33. Augello C, Vaira V, Caruso L, et al: MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int 32: 772-782, 2012.